CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
CalciMedica (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies, announced its participation in the upcoming H.C. Wainwright Global Investment Conference. CEO Rachel Leheny, Ph.D. will present on September 8, 2025, at 3:30 p.m. ET.
The presentation will be available via live webcast in the "IR Events and Presentations" section of CalciMedica's website, with a replay accessible for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction 13 Alerts
On the day this news was published, CALC gained 14.81%, reflecting a significant positive market reaction. Argus tracked a peak move of +14.7% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $45M at that time. Trading volume was exceptionally heavy at 7.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
A live webcast of the presentation can be accessed in the "IR Events and Presentations" section of CalciMedica's IR website. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA –NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated respiratory failure. For more information, please visit www.calcimedica.com.
Contact Information
Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302542326.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the H.C. Wainwright Conference?
How can investors access CalciMedica's (CALC) H.C. Wainwright presentation?
What type of therapies is CalciMedica (CALC) developing?
Who will represent CalciMedica (CALC) at the H.C. Wainwright Conference?
